Clinical Trials Sponsored by Parion Sciences

Total 19969 results

Gilead Sciences

Completed

PROPHYSOME: Pilot Study on Safety of a Weekly Administration of 10mg/kg of AmBisome® in Antifungal Prophylaxis Treatment of Allogeneic Stem-cell Transplantation and Acute Leukaemia

Leukemia

France
Gilead Sciences

Completed

Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

Hungary, Czech Republic
Gilead Sciences

Completed

Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving Chemotherapy for Acute Lymphoblastic Leukemia (AmBiGuard)

Invasive Fungal Disease

United Kingdom
Gilead Sciences

Completed

Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

HIV Infections | Acquired Immunodeficiency Syndrome

United States
Gilead Sciences

Completed

Sofosbuvir Plus Ribavirin in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection

Hepatitis C Virus

United States
Gilead Sciences

Completed

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States, Russian Federation, Thailand, Serbia, Poland, Hungary, Malaysia, South Africa, Ukraine, Czech Republic, Romania, Slovakia
Gilead Sciences

Completed

Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3

Chronic Hepatitis C Infection

New Zealand
Gilead Sciences

Completed

A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects

HIV Infections

France, Spain, United Kingdom, Belgium, Italy, Germany, Netherlands, Portugal, Austria, Ireland, Poland, Sweden, Switzerland
Gilead Sciences

Completed

Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging

Myocardial Ischemia | Myocardial Perfusion Imaging

United States, Finland, Israel, Canada, Italy, Singapore, Czech Republic, United Kingdom
Gilead Sciences

Completed

Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways (PALS)

Cystic Fibrosis | Pseudomonas Aeruginosa

Spain, United States, Germany, France, Italy, Poland
Gilead Sciences

Completed

Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon (POSITRON)

Chronic Hepatitis C

United States, Canada, New Zealand, Puerto Rico, Australia
Gilead Sciences

Completed

A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma

Diffuse Scleroderma | Limited Scleroderma

Australia
Gilead Sciences

Terminated

(ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF (ARTEMIS-IPF)

Idiopathic Pulmonary Fibrosis

Belgium, France, Germany, Israel, Spain, United States, Switzerland, Colombia, Mexico, Italy, Czech Republic, Australia, Canada, Austria, Poland, United Kingdom, Argentina, Netherlands, Peru, Ireland, Brazil, Chile
Gilead Sciences

Completed

Evaluation of the Quality of Life Questionnaire-Bronchiectasis (QOL-B) in Patients With Bronchiectasis

Bronchiectasis

United States
Gilead Sciences

Completed

DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension

Hypertension

United States, Spain, Germany, Argentina, Denmark, Brazil, Canada, France, Sweden, United Kingdom, Italy
Gilead Sciences

Completed

Truvada Versus Truvada Plus Hepatitis B Immunoglobulin (HBIg) in Prevention of Chronic Hepatitis B Recurrence Post Liver Transplant

Chronic Hepatitis B

United States
Gilead Sciences

Completed

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species Infection

Cystic Fibrosis | Burkholderia Infections

United States, Canada
Alimera Sciences

Completed

Pharmacokinetic and Efficacy Study of Fluocinolone Acetonide Inserts in Patients With Diabetic Macular Edema

Diabetic Macular Edema

United States
Gilead Sciences

Terminated

Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus Infection

HCV Infection

United States, United Kingdom, Germany, Canada, Puerto Rico, Poland
Gilead Sciences

Completed

Pilot Study of Simtuzumab in the Treatment of Liver Fibrosis

Liver Fibrosis

United States
Gilead Sciences

Approved for marketing

Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis C

Post-transplant Hepatitis C
Gilead Sciences

Terminated

ESSENTIAL-"The Studies of Oral Enoximone Therapy in Advanced Heart Failure"

Heart Failure, Congestive
Gilead Sciences

Completed

Study Evaluating Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients With Pseudomonas Aeruginosa Lung Infection

Cystic Fibrosis

United States
Gilead Sciences

Completed

GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection

Hepatitis C, Chronic

United States, Germany
Gilead Sciences

Completed

A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects

Ischemic Heart Disease

United States
Gilead Sciences

Completed

Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection

HCV Infection

United Kingdom, Germany, Ireland, United States, Belgium, Puerto Rico, Poland
Gilead Sciences

Completed

Evaluate Efficacy, Safety and PK of Adefovir Dipivoxil Liquid Suspension in Patients With Chronic Hepatitis B

Chronic Hepatitis B

United States
Gilead Sciences

Completed

A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

Chronic Hepatitis C

United States, Puerto Rico
Gilead Sciences

Completed

Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial Hypertension

Pulmonary Hypertension
Gilead Sciences

Completed

A Phase 1 Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of GS-5806

RSV Infection

United States
Gilead Sciences

Completed

A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

HCV Infection

United States
Gilead Sciences

Withdrawn

A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia
Gilead Sciences

Completed

Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1) (ATHENA-1)

Pulmonary Arterial Hypertension

United States
Gilead Sciences

Completed

Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg

Type 2 Diabetes Mellitus

United States
Gilead Sciences

Completed

Safety and Efficacy Study of Switching From Epzicom to Truvada (SWIFT)

HIV Infection

United States, Puerto Rico, Canada
Gilead Sciences

Completed

Phase 2 Extension Study of Ambrisentan in Pulmonary Arterial Hypertension

Pulmonary Hypertension
Gilead Sciences

Completed

CHARM: Chronic Hepatitis B Antihepadnaviral Resistance Mutation Study (CHARM)

Chronic Hepatitis B

Australia
Gilead Sciences

Completed

ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla (ONCE)

HIV Infections

United Kingdom
Gilead Sciences

Completed

Study to Investigate Effects of CAL-263 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber

Allergic Rhinitis

Austria
Gilead Sciences

Completed

International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa (AIR-CF1)

Cystic Fibrosis

United States, Canada, Australia, New Zealand
Gilead Sciences

Completed

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa (AIR-CF2)

Cystic Fibrosis

United States
Gilead Sciences

Completed

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa (AIR-CF4)

Cystic Fibrosis | Pseudomonas Aeruginosa | Lung Infection

United States, Australia, Canada
Gilead Sciences

Completed

ROCKET I - Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation Trial (ROCKET I)

HIV Infections

United Kingdom
Gilead Sciences

Completed

ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH)

Pulmonary Hypertension

United States, Australia, Canada
Gilead Sciences

Completed

Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients

HIV Infections

United States
Gilead Sciences

Completed

Study of BSF 208075 Evaluating Exercise Capacity in Patients With Pulmonary Arterial Hypertension

Pulmonary Hypertension

United States, Germany, Australia, Belgium, France, Italy
Gilead Sciences

Completed

Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.

Pulmonary Arterial Hypertension
Gilead Sciences

Completed

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.

Pulmonary Arterial Hypertension
Gilead Sciences

Completed

Evaluation of Chronic HBV Patients w/Evidence of HBV Replication and Normal or Minimally Elevated Liver Transaminases.

Chronic Hepatitis B

United States
Gilead Sciences

Completed

Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.

HIV | Human Immunodeficiency Virus | HIV-1

United States, Puerto Rico

3

Subscribe